Burrill honours biotech's 'best of 2004'
Monday, 18 October, 2004
San Francisco-based biotechnology investment bank Burrill & Co has named its 'best of biotech' for 2004.
Now in their 17th year, the awards are presented at Burrill's annual Laguna Niguel biotech meeting, and the winners are chosen by a vote among industry CEOs. "There is no greater recognition than that of one's peers," commented Burrill & Co CEO Steven Burrill.
The 2004 winners are:
- Most important new financing (public): Eyetech (CEO David Guyer), for its US $157M IPO in January, which gave the ophthalmic therapeutic developer a post-money valuation of $831.6 million.
- Most important new financing (private):: Jazz (CEO Samuel Saks), which raised US$250 million in the biggest biotech venture round ever, a series B round led by Kohlberg Kravis Roberts.
- Best new approved product (therapeutic): Genentech, its Avastin bevacizumab as a first-line treatment for metastatic colorectal cancer in combination with 5-fluorouracil (5-FU). The humanised monoclonal antibody against vascular endothelial growth factor (VEGF) is the first FDA-approved cancer therapy designed to inhibit angiogenesis.
- Best new approved product (other): OraSure's OraQuick HIV-1/2 test to detect HIV-2 antibodies in oral fluid samples.
- Most creative and significant deal: Amgen/Biovitrum, US$522M+ (CEO Mats Pettersson). In September 2003, Biovitrum granted Amgen exclusive rights to develop its small molecule 11beta-hydroxysteroid dehydrogenase type 1 (11b HSD-1) enzyme inhibitors, including lead compound BVT.3498, which is in Phase II testing for Type II diabetes.
- Most creative and significant merger and/or acquisition: Biogen/Idec's US$6.7 billion merger, November 2003 (CEO and president, James Mullen).
The meeting also inducted new appointees into a 'biotech hall of fame':
- Special recognition (company): Genetics Institute (Chairman, president, CEO Robert Essner), the developer of arthritis drug Enbrel.
- Special recognition (individual): Francis Crick, who passed away this year, renowned for elucidating the structure of DNA.
- Scientific achievement: Judah Folkman conducted pioneering research on the mechanism of angiogenesis, opening a field of investigation now pursued worldwide.
Quitting smoking increases life expectancy even for seniors
Although the benefits of quitting smoking diminish with age, there are still substantial gains...
Stem cell transplants treat blindness in mini pigs
Scientists have successfully transplanted retinas made from stem cells into blind mini pigs,...
Sugary drinks raise cardiovascular disease risk, but occasional sweets don't
Although higher sugar intake raises your risk of certain cardiovascular diseases, consuming sweet...
